1. An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies 
Thomas C. Shea, Rebecca Bruner, Joseph M. Wiley, Jonathan S. Serody, Scott Sailer, Don A. Gabriel, Eileen Capel, Dominic T. Moore, Georgette Dent, Stuart Bentley, Mark E. Brecher 
Biology of Blood and Marrow Transplantation 
Volume 9, Issue 7, Pages (July 2003)
DOI: /S (03)

2. Figure 1
Probability of (A) relapse-free or (B) overall survival for all 60 patients by disease group. ALL, solid line; acute myeloid or acute promyelocytic leukemia (AML or APL), dashed line; LGL-NHL, dotted line; Hodgkin’s disease, intermediate- or high-grade NHL (HD, ILG-NHL or HGL-NHL) dotted-dashed line; multiple myeloma (MM) thick dotted-dashed line.
Biology of Blood and Marrow Transplantation 2003 9, DOI: ( /S (03) )

3. Biology of Blood and Marrow Transplantation 2003 9, 443-452DOI: (10
Biology of Blood and Marrow Transplantation 2003 9, DOI: ( /S (03) )